| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 52.70 | 0.5% |
| Total Income | 52.70 | 0.5% |
| Expenditure | 51.46 | 7.9% |
| PBT | 0.07 | 101.2% |
| Net Profit | -0.02 | 99.7% |
| OPM | 2.35% | 8.87pp |
| NPM | -0.04% | 10.85pp |
| EPS | 0.00 | 100.0% |
Cerus Corp. Reports Record Q3 2025 Revenue, Raises FY25 Guidance
04 May 2026 · 4 May, 7:48 am
Summary
Cerus Corporation announced its financial results for the third quarter ended September 30, 2025. Total revenue for the quarter was $60.2 million, a 19% increase year-over-year, driven by record product revenue of $52.7 million, which grew 15% year-over-year. The company's net loss attributable to Cerus narrowed to $0.02 million, and non-GAAP adjusted EBITDA totaled $5.0 million. Cerus is raising its full-year 2025 product revenue guidance to a range of $202 million to $204 million.
Key Highlights
- 1
Cerus Corporation's third quarter total revenue increased by 19% to $60.2 million.
- 2
Product revenue for the third quarter reached a record $52.7 million, up 15% year-over-year.
- 3
Hospital demand for INTERCEPT fibrinogen complex (IFC) in the U.S. increased approximately 110% compared to the prior year period.
- 4
The company narrowed its third quarter GAAP net loss attributable to Cerus to $0.02 million, near breakeven.
- 5
Non-GAAP adjusted EBITDA for the third quarter totaled $5.0 million.
- 6
Cerus is raising its full-year 2025 product revenue guidance range to $202 million - $204 million.
- 7
Cash, cash equivalents, and short-term investments totaled $78.5 million at September 30, 2025.
Management Comments
William “Obi” Greenman
“We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Furthermore, hospital demand for INTERCEPT fibrinogen complex or IFC in the U.S. continues to increase, bolstered by the many positive case studies from large academic hospitals that have implemented IFC in routine use,”
Informational and educational content only. Not investment advice.